Pharmacokinetics of midazolam in resuscitated patients treated with moderate hypothermia

International Journal of Clinical Pharmacy

Volumn 35, Issue 2, 2013, Pages 210-216

  Bastiaans, Diane E T ^a   Swart, Eleonora L ^b   Van Akkeren, Jesse P ^a   Derijks, Luc J J ^a  

^a MÁXIMA MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Hypothermia; Midazolam; Pharmacokinetics; Resuscitation

Indexed keywords

1 OH MIDAZOLAM; 1 OH MIDAZOLAM GLUCURONIDE; ATRACURIUM BESILATE; MIDAZOLAM; NITRAZEPAM; UNCLASSIFIED DRUG; HYPNOTIC SEDATIVE AGENT;

ADULT; AGED; ARTICLE; BODY TEMPERATURE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COOLING; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; HYPOTHERMIA; INTENSIVE CARE UNIT; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESUSCITATION; SEDATION; WARMING; BIOLOGICAL MODEL; COMA; INDUCED HYPOTHERMIA; METHODOLOGY; NETHERLANDS; NONLINEAR SYSTEM; PROSPECTIVE STUDY; TEMPERATURE; TISSUE DISTRIBUTION;

AGED; COMA; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; HYPOTHERMIA, INDUCED; INTENSIVE CARE UNITS; MALE; MIDAZOLAM; MIDDLE AGED; MODELS, BIOLOGICAL; NETHERLANDS; NONLINEAR DYNAMICS; PROSPECTIVE STUDIES; RESUSCITATION; TEMPERATURE; TISSUE DISTRIBUTION;

EID: 84884487389     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-012-9725-0     Document Type: Article

References (11)

1. Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, et al. Treatment of comatose survivors of out-ofhospital cardiac arrest with induced hypothermia. N Engl J Med. 2002;346: 557-63.
2. Group HaCAS. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346: 549-56.
3. Fukuoka N, Aibiki M, Tsukamoto T, Seki K, Morita S. Biphasic concentration change during continuous midazolam administration in brain-injured patients undergoing therapeutic moderate hypothermia. Resuscitation. 2004;60: 225-30.
4. Bauer TM, Ritz R, Haberthur C, Ha HR, Hunkeler W, Sleight AJ, et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet. 1995;346: 145-7.
5. Swart EL, Zuideveld KP, de Jongh J, Danhof M, Thijs LG, Strack van Schijndel RM. Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. Br J Clin Pharmacol. 2004;57: 135-45.
6. Rossen RV, Trumpie H. Onverklaarbare midazolamcoma's mogelijk verklaard. Extract. 1996;7: 3.
7. Vletter AA, Burm AG, Breimer LT, Spierdijk J. High-performance liquid chromatographic assay to determine midazolam and flumazenil simultaneously in human plasma. J Chromatogr. 1990;530: 177-85.
8. Chen M, Ma L, Drusano GL, Bertino JS Jr, Nafziger AN. Sex differences in CYP3A activity using intravenous and oral midazolam. Clin Pharmacol Ther. 2006;80: 531-8.
9. Vree TB, Shimoda M, Driessen JJ, Guelen PJ, Janssen TJ, Termond EF, et al. Decreased plasma albumin concentration results in increased volume of distribution and decreased elimination of midazolam in intensive care patients. Clin Pharmacol Ther. 1989;46: 537-44.
10. Mc Donnell CG, Shorten G, Van Pelt FN. Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro. Anaesthesia. 2005;60: 747-53.
11. Hostler D, Zhou J, Tortorici MA, Bies RR, Rittenberger JC, Empey PE, et al. Mild hypothermia alters midazolam pharmacokinetics in normal healthy volunteers. Drug Metab Dispos. 2010;38: 781-8.